BEIJING - China’s largest contract research organization has joined the ranks of domestic innovative drug makers, establishing a unit billed as a gateway to China for global innovators.
WuXi’s New Unit Joins Race For Drug Innovation In China
WuXi is opening up its service platform, manufacturing capacity and pockets, aiming to develop global biotech innovations in China faster and cost-effectively. The strategy may draw on a template of a joint venture with MedImmune and a contract manufacturing deal for Ambrx already in place.